In this trial, CPZ has been added to the standard GBM treatment in patients carrying a tumor with a hypo-methylated MGMT gene promoter and thus characterized by resistance to TMZ and poorer prognosis [37]. The gene discussed is MGMT; the disease is glioblastoma.